25.04.2022 • News

Milliken Expands German Plastics Modifiers Capacity

US specialty chemical company Milliken is expanding the facilities it acquired last March when it took over Germany’s Zebra-chem. Located in Bad Bentheim, Zebra-chem is a specialty compounder and chemicals company that makes additive and blowing agent concentrates for polyolefins, PVC and engineering thermoplastics.

With the installation of new manufacturing equipment, the expansion will increase capacity at the plant by 60% by the end of 2022,  Milliken said, adding that it is on track to fully integrate the Zebra-chem acquisition this year.

The viscosity modifiers and performance modifiers made at the facility, which will be renamed Birch I, increase the melt flow of recycled PP resins with little to no loss of physical properties, enabling converters and brand owners to use more recycled content without compromising overall performance, Milliken said. The company has also built a new warehouse nearby, named Birch II.

“We are seeing very strong demand from several end markets where these products are adding value, and our customer base has welcomed our broader solution portfolio,” said Milliken sales manager Tugce Asici-van Houselt. “These facilities will continue to serve the global market, with a focus on Europe, the Middle East and Africa.”

Author: Elaine Burridge, Freelance Journalist

© 2022 Milliken & Company
© 2022 Milliken & Company

Free Virtual Event

Batteries and Hydrogen: Competitors or Partners?
CHEManager Spotlight

Batteries and Hydrogen: Competitors or Partners?

17 September 2026 | Reserve your spot to learn where solid-state batteries and green hydrogen are headed—and how leading teams are turning them into scalable energy storage solutions.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read